Top Page
IRLAB Therapeutics AB Class A
(IRLAB.A)
IRLAB Therapeutics AB Class A (IRLAB.A) vs. iShares MSCI Sweden ETF (EWD)
IRLAB Therapeutics AB Class A Business Overview & Revenue Model
IRLAB Therapeutics AB Class A Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 85.56M | 94.63M | 5.68M | 61.14M | 207.78M | 300.00K |
| Gross Profit | -33.35M | -92.42M | -122.73M | -111.23M | 168.69M | -1.70M |
| EBITDA | -68.62M | -68.07M | -173.32M | -109.13M | 55.79M | -89.46M |
| Net Income | -91.91M | -83.13M | -177.84M | -114.20M | 51.78M | -91.85M |
Balance Sheet | ||||||
| Total Assets | 170.55M | 136.21M | 177.12M | 323.56M | 472.45M | 370.07M |
| Cash, Cash Equivalents and Short-Term Investments | 110.13M | 66.92M | 111.31M | 252.78M | 401.90M | 277.01M |
| Total Debt | 29.81M | 60.42M | 27.57M | 3.98M | 6.60M | 2.93M |
| Total Liabilities | 116.34M | 103.58M | 61.36M | 32.72M | 72.97M | 22.19M |
| Stockholders Equity | 54.21M | 32.63M | 115.76M | 290.83M | 399.48M | 347.88M |
Cash Flow | ||||||
| Free Cash Flow | -53.65M | -65.79M | -165.14M | -145.99M | 127.93M | -89.61M |
| Operating Cash Flow | -53.65M | -65.59M | -164.85M | -142.61M | 128.64M | -89.21M |
| Investing Cash Flow | 0.00 | -199.00K | -293.00K | -3.38M | -708.00K | -394.00K |
| Financing Cash Flow | 73.39M | 21.40M | 23.68M | -3.13M | -3.04M | 256.09M |
IRLAB Therapeutics AB Class A Technical Analysis
IRLAB Therapeutics AB Class A Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr287.33M | -17.23 | -48.30% | ― | ― | 52.96% | |
47 Neutral | kr207.41M | -10.52 | ― | ― | ― | ― | |
44 Neutral | kr201.69M | -2.50 | -51.35% | ― | ― | -34.02% | |
44 Neutral | kr266.99M | -4.84 | ― | ― | -7.68% | 17.93% | |
41 Neutral | kr116.78M | -1.38 | -1291.15% | ― | ― | 28.54% | |
40 Underperform | kr169.88M | -1.27 | -199.86% | ― | 69.03% | 23.10% |
IRLAB Therapeutics AB Class A Corporate Events
IRLAB Therapeutics has obtained regulatory and ethical approval to initiate a Phase Ib clinical study of its drug candidate IRL757 in Parkinson’s disease patients suffering from apathy, a disabling symptom for which no approved treatments currently exist. The fully MSRD-funded trial will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland and Spain, building on earlier Phase I studies in healthy adults that demonstrated good absorption, systemic exposure and no serious adverse events. IRL757, which has shown positive effects on cognitive function and motivation in preclinical models through its proposed ability to restore disrupted cortical–subcortical nerve signalling, is being advanced under a collaboration with Otsuka group’s McQuade Center and could emerge as the first approved therapy for apathy in Parkinson’s and other neurodegenerative diseases, targeting a large, currently underserved patient population in the US, Europe and other major markets.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK2.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics AB announced that the European Patent Office intends to grant a new patent for mesdopetam, covering various salt forms of the drug candidate. This patent enhances the intellectual property portfolio of mesdopetam, supporting its market exclusivity and commercialization efforts, which could significantly impact the company’s operations and industry positioning by extending market exclusivity into the mid-2040s across major markets.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK2.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics AB announced its participation in the Redeye Technology & Life Science Day 2025, where CEO Kristina Torfgård and EVP Nicholas Waters will present and engage in a Q&A session. This event highlights IRLAB’s active engagement in the scientific community and provides a platform to showcase its advancements in Parkinson’s disease treatments, potentially strengthening its industry position and stakeholder relations.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK2.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics AB has announced the appointment of its nomination committee for the 2026 annual general meeting. The committee includes representatives from the company’s largest shareholders, collectively holding about 36% of shares and votes, and will present proposals for the AGM scheduled for May 20, 2026. This move is part of IRLAB’s ongoing corporate governance efforts, reflecting its commitment to shareholder engagement and strategic planning.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK2.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics announced the acceptance of two abstracts for presentation at the AD/PD 2026 conference, highlighting their research on Parkinson’s disease. This participation is expected to enhance their scientific network and boost confidence in their drug development pipeline, potentially impacting their position in the industry.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK2.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics AB’s interim report for January to September 2025 highlights significant developments, including a successful rights issue that has secured necessary capital for advancing drug candidates IRL1117 and pirepemat. The company also submitted a clinical trial application for a Parkinson’s study to the EMA and received additional funding for the IRL757 study. A new patent for mesdopetam was granted in China, ensuring market exclusivity into the mid-2040s. Financially, the company reported a decrease in net sales and operating profit compared to the previous year, but cash reserves have increased.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK2.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics AB announced a presentation and webcast for its Q3 2025 interim report, scheduled for October 29, 2025. The event will feature insights from CEO Kristina Torfgård and EVP Nicholas Waters, focusing on the company’s financial performance and ongoing research developments. This announcement highlights IRLAB’s commitment to transparency and stakeholder engagement, potentially impacting its market positioning and investor relations.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics has appointed Gustaf Albèrt as the new Chief Financial Officer, effective November 17, 2025. Albèrt brings extensive experience from senior financial roles in the biotech sector, including positions at Isofol Medical and Aqilion. His appointment is expected to bolster IRLAB’s management team as the company continues its focus on value creation and advancing its pipeline of Parkinson’s disease treatments.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics announced that CEO Kristina Torfgård will present at the Redeye Theme: Neurology event in Stockholm, providing an opportunity to engage with Swedish and international investors. This presentation could enhance IRLAB’s network and potentially lead to new collaborations, reinforcing its position in the neurology sector.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.